FDA approves gefurulimab for myasthenia gravis - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

FDA approves gefurulimab for myasthenia gravis

  • By

  • Mouj Hijazi

  • November 16, 2026

  • 3 min

Share

Clinical Scorecard: FDA approves gefurulimab for myasthenia gravis

At a Glance

CategoryDetail
ConditionClinical topic addressed by the source article: FDA approves gefurulimab for myasthenia gravis
Key MechanismsMechanisms or clinical associations described in the source article.
Target PopulationPopulation described in the source article.
Care SettingFDA-approved treatment administered subcutaneously once weekly; patients or caregivers may administer it after appropriate training. Access is through a restricted REMS.

Key Highlights

  • The FDA approved gefurulimab-gaks (Klygefa) for adults with AChR antibody-positive gMG.
  • In the 26-week PREVAIL trial, MG-ADL scores improved by 4.2 points with gefurulimab and 2.6 points with placebo; the treatment difference was −1.6 points.
  • The key secondary endpoint, Quantitative Myasthenia Gravis score, improved by 4.5 points with gefurulimab and 2.4 points with placebo.
  • The approved regimen uses a weight-based loading dose followed by weekly subcutaneous dosing.
  • The prescribing information includes a boxed warning for serious meningococcal infections and requires meningococcal vaccination and REMS participation.

Guideline-Based Recommendations

Diagnosis

  • FDA approval is for adults with AChR antibody-positive gMG.

Management

  • For patients weighing less than 80 kg, administer 600 mg on day 1, then 300 mg once weekly starting on day 8.
  • For patients weighing 80 kg or more, administer 900 mg on day 1, then 600 mg once weekly starting on day 8.
  • Patients or caregivers may administer treatment after appropriate training.
  • Gefurulimab is available only through a REMS requiring prescriber certification, patient counseling, and vaccination assessment.

Monitoring & Follow-up

  • Assess meningococcal vaccination status before treatment; the prescribing information requires vaccination at least 2 weeks before treatment, with antibacterial prophylaxis when urgent treatment is necessary in patients not up to date with vaccination.
  • The PREVAIL primary endpoint was change from baseline in MG-ADL total score at week 26.

Risks

  • The boxed warning addresses serious meningococcal infections.
  • Do not initiate treatment in patients with unresolved serious Neisseria meningitidis infection.
  • If urgent treatment is needed in a patient not up to date with meningococcal vaccination, antibacterial prophylaxis is required.
  • In PREVAIL, injection-site reactions occurred in 12% of gefurulimab recipients versus 3% with placebo; back pain in 8% versus 2%; and vomiting in 5% versus 1%.

Patient & Prescribing Data

FDA-approved for adults with AChR antibody-positive gMG. PREVAIL enrolled 260 adults with MGFA class II–IV disease and MG-ADL scores of at least 5; participants continued eligible background therapies at stable doses.

In PREVAIL, 65.5% of gefurulimab recipients achieved at least a 3-point MG-ADL improvement at week 26, compared with 52.2% receiving placebo. AstraZeneca reported improvement beginning at week 1 and maintained through week 26.

Clinical Best Practices

  • Prescribing-information requirement: assess meningococcal vaccination status and vaccinate at least 2 weeks before treatment; use antibacterial prophylaxis when urgent treatment is necessary for a patient not up to date with vaccination.
  • Do not initiate gefurulimab in patients with unresolved serious Neisseria meningitidis infection.
  • Complete REMS requirements, including prescriber certification, patient counseling, and vaccination assessment.

Related Resources & Content

Original Source(s)

Related Content